~~<i id='795430AA4C'><strike id='795430AA4C'><tt id='795430AA4C'><pre id='795430AA4C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：hotspot 2025-09-14 10:00:09 - browse：5928

Trump Campaign Event In Nevada — Ethan Miller/Getty Images

WASHINGTON — Former President Trump is back to campaigning for tying Medicare drug prices to lower prices abroad.

In Trump fashion, he claimed in a video announcement this month that he is the “only president in modern times” to take on the drug industry — and dinged President Biden directly.

“Biden canceled my tough-on-pharma policies the moment he had a chance,” Trump said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Stoke drug shows lower activity against childhood epilepsy

hotspot

entertainment

knowledge

leisure time

focus

YichuanCao/SipaUSAWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechn

WSS

Biden announces an advanced cancer research initiative

As the dark side of IVF slowly comes into focus, even more transparency is needed

Medical mystery: When a cough is not just a cough

Gilead might be held responsible for not developing a drug

The mammogram wars are not over

What we’ve learned from the Aduhelm mess

hotspot

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Hepatitis C has a cure — but many Americans still lack access to it

The dental labor crisis is a moment of opportunity

23andMe had bad news about my health. I wish a person had delivered it

What should King Charles tell the public about his cancer?

United colonoscopy coverage change 'may cost lives,' doctors say

Will biotech layoffs continue through 2023?

Walensky prepares to leave CDC — and Congress — behind

Biden jokes that Republicans may impeach him because inflation is starting to cool down

entertainment

To avoid data mishandling cases, universities eye AI and other tools

VC firm RA Capital starts a new synthetic biology incubator

Behind warning on Apellis’s eye drug lies a conflict of interest

PhRMA lawsuit over Medicare drug price negotiation tossed

What we’ve learned from the Aduhelm mess

A disappointing year of Humira biosimilars

knowledge

knowledge

leisure time

focus